Retatrutide targets three metabolic receptors for fat oxidation, insulin sensitivity, and body recomposition
Developer: Eli Lilly and Company Classification: Triple Agonist (GIP/GLP-1/Glucagon receptors) Administration: Once-weekly subcutaneous injection Development Status: Phase 3 clinical trials Expected FDA Approval: Q3 2026 to Q1 2027 Developer: Boehringer Ingelheim Classification: Dual Agonist (Glucagon/GLP-1 receptors) Administration: Once-weekly subcutaneous injection Development Status: Phase 3 clinical trials (SYNCHRONIZE program) Regulatory Status: FDA Breakthrough Therapy designation for MASH Retatrutide emerged from Eli Lillys research into multi-receptor agonism
It shows up above all in more hair in the brush, in the shower and on the pillow
High-dose creatine being rewritten as a cognitive and neurological supplement
In PD, several GLP-1RAs have demonstrated promising disease-modifying effects in phase II RCTs, and the results of phase III trials are anticipated
Based on published clinical data, oral semaglutide 25 mg daily produces steady-state plasma exposures that approach but may not fully match injectable 2.4 mg weekly (Wegovy)
